Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 27:1:100002.
doi: 10.1016/j.jlb.2023.100002. eCollection 2023 Sep.

Liquid biopsy: Cell-free DNA based analysis in breast cancer

Affiliations
Review

Liquid biopsy: Cell-free DNA based analysis in breast cancer

Konstantinos Venetis et al. J Liq Biopsy. .

Abstract

Breast cancer management has witnessed significant advancements, especially in the diagnosis and treatment response monitoring through the implementation of imaging techniques and tissue biopsy procedures. Nevertheless, there is potential for further improvement by integrating less invasive approaches that offer timely and precise information. Liquid biopsy, which involves isolating tumor-derived components such as circulating cell-free DNA (cfDNA) and its subset known as circulating tumor DNA (ctDNA), can greatly enhance the prognosis, identification of specific genomic alterations, and selection of targeted therapies for breast cancer patients. While the incorporation of ctDNA-based testing into clinical practice has been primarily focused on metastatic breast cancer (MBC), there is growing interest in its applicability in early-stage breast cancer given the ability to capture tumor heterogeneity. Additionally, the minimally invasive nature of ctDNA testing allows for multiple serial samplings, providing a dynamic assessment of tumor characteristics and monitoring treatment response over time. However, the analysis of ctDNA in breast cancer encounters a significant challenge related to its abundance and the temporal aspect of the disease. The quantity of ctDNA in relation to the disease stage poses an important obstacle that often hinders its accurate analysis. Therefore, it is crucial to ensure timely sample collection, employ sensitive detection methods, and carefully manage the pre-analytical phase to overcome these challenges and facilitate successful ctDNA analysis in breast cancer. This article aims to summarize the methodologies employed in the detection of ctDNA, provide a comprehensive review of the current applications of ctDNA analysis in breast cancer, and elucidate the underlying rationale for its potential extension into broader clinical contexts. Furthermore, models that could facilitate the widespread adoption of ctDNA testing in various healthcare institutions are discussed.

Keywords: Biomarkers; Breast cancer; Liquid biopsy; cfDNA; ctDNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Circulating tumor DNA (ctDNA) testing for actionable biomarkers assessment in breast cancer. Analysis of ctDNA isolated from plasma after centrifugation of peripheral blood can be used for the investigation of mutations in clinically relevant biomarkers. Detection methods employed for ctDNA analysis are also showcased, tailored to the specific biomarker of interest.
Fig. 2
Fig. 2
Comparison between network topology models to improve ctDNA testing in breast cancer. On the left is reported the ‘Hub and spoke model’, a network topology where a central “Hub” serves as the central point for the analytical and post-analytical phases, connecting with multiple peripheral “spoke” structures. On the right is shown the ‘point-to-point model’, a network topology where each “point” structure is directly connected to another “point” structure through a dedicated communication link. In contrast to the ‘Hub and spoke model’, all points perform the pre-analytical, analytical, and post-analytical phases.

References

    1. S. Addanki, S. Meas, V. N. Sarli, B. Singh, and A. Lucci, "Applications of circulating tumor cells and circulating tumor DNA in precision oncology for breast cancers," Int J Mol Sci, vol. 23, no. 14, doi: 10.3390/ijms23147843. - PMC - PubMed
    1. Ginsburg O., et al. Breast cancer early detection: a phased approach to implementation. Cancer. May 15 2020;126(Suppl 10):2379–2393. doi: 10.1002/cncr.32887. in eng. Suppl 10. - DOI - PMC - PubMed
    1. Thill M., et al. AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2019. Breast Care. Aug 2019;14(4):247–255. doi: 10.1159/000500999. (in eng) - DOI - PMC - PubMed
    1. Speirs V. Quality considerations when using tissue samples for biomarker studies in cancer research. Biomark Insights. 2021;16 doi: 10.1177/11772719211009513. (in eng) - DOI - PMC - PubMed
    1. Overman M.J., et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol. Jan 1 2013;31(1):17–22. doi: 10.1200/jco.2012.43.1718. in eng. - DOI - PMC - PubMed

LinkOut - more resources